The human side of microglia

Trends in Neurosciences

Volumn 37, Issue 3, 2014, Pages 125-135

  Smith, Amy M ^a   Dragunow, Mike ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Clinical translation; Neuroimmunology; Neuroinflammation; Primary cell culture; Species differences

Indexed keywords

NITRIC OXIDE; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN; TRANSFORMING GROWTH FACTOR BETA1;

AGING; BASIC RESEARCH; BIOCHEMISTRY; BRAIN TISSUE; CELL FUNCTION; CULTURE TECHNIQUE; HUMAN; MEDICAL RESEARCH; MICROGLIA; NERVE CELL DIFFERENTIATION; NEUROIMMUNOLOGY; NONHUMAN; PLURIPOTENT STEM CELL; REVIEW; SPECIES DIFFERENCE;

CLINICAL TRANSLATION; NEUROIMMUNOLOGY; NEUROINFLAMMATION; PRIMARY CELL CULTURE; SPECIES DIFFERENCES;

ANIMALS; HUMANS; MICROGLIA; MODELS, ANIMAL; SPECIES SPECIFICITY;

EID: 84894464622     PISSN: 01662236     EISSN: 1878108X     Source Type: Journal    
DOI: 10.1016/j.tins.2013.12.001     Document Type: Review

References (161)

1. Khanna R., Burrows S.R. Human immunology: a case for the ascent of non-furry immunology. Immunol. Cell Biol. 2011, 89:330-331.
2. Rivera J., Tessarollo L. Genetic background and the dilemma of translating mouse studies to humans. Immunity 2008, 28:1-4.
3. van der Worp H.B., et al. Can animal models of disease reliably inform human studies?. PLoS Med. 2010, 7:e1000245. 10.1371/journal.pmed.1000245.
4. Schneemann M., Schoeden G. Macrophage biology and immunology: man is not a mouse. J. Leukoc. Biol. 2007, 81:579.
5. Mestas J., Hughes C.C.W. Of mice and not men: differences between mouse and human immunology. J. Immunol. 2004, 172:2731-2738.
6. Pound P., et al. Where is the evidence that animal research benefits humans?. BMJ 2004, 328:514-517.
7. Leist M., Hartung T. Inflammatory findings on species extrapolations: humans are definitely no 70-kg mice. Arch. Toxicol. 2013, 87:563-567.
8. Matthews R.A. Medical progress depends on animal models - doesn't it?. J. R. Soc. Med. 2008, 101:95-98.
9. Rice J. Animal models: not close enough. Nature 2012, 484:S9.
10. Hackam D., Redelmeier D. Translation of research evidence from animals to humans. JAMA 2006, 296:1727-1732.
11. Dragunow M. The adult human brain in preclinical drug development. Nat. Rev. 2008, 7:659-666.
12. Church D., et al. Lineage-specific biology revealed by a finished genome assembly of the mouse. PLoS Biol. 2009, 7:e1000112. 10.1371/journal.pbio.1000112.
13. Seok J., et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:3507-3512.
14. Davis M.M. Immunology taught by humans. Sci. Transl. Med. 2012, 4. 10.1126/scitranslmed.3003385.
15. Virgin H.W., et al. Redefining chronic viral infection. Cell 2009, 138:30-50.
16. Gevers D., et al. The Human Microbiome Project: a community resource for the healthy human microbiome. PLoS Biol. 2012, 10:e1001377. 10.1371/journal.pbio.1001377.
17. Loerch P.M., et al. Evolution of the aging brain transcriptome and synaptic regulation. PLoS ONE 2008, 3:e3329. 10.1371/journal.pone.0003329.
18. Bishop N.A., et al. Neural mechanisms of ageing and cognitive decline. Nature 2010, 464:529-535.
19. Ito D., et al. Microglia-specific localisation of a novel calcium binding protein, Iba1. Mol. Brain Res. 1998, 57:1-9.
20. Smith A.M., et al. The transcription factor PU.1 is critical for viability and function of human brain microglia. Glia 2013, 61:929-942.
21. Walton M.R., et al. PU.1 expression in microglia. J. Neuroimmunol. 2000, 104:109-115.
22. Gómez-Nicola D., et al. Regulation of microglial proliferation during chronic neurodegeneration. J. Neurosci. 2013, 33:2481-2493.
23. Otero K., et al. Macrophage colony-stimulating factor induces the proliferation and survival of macrophages via a pathway involving DAP12 and [beta]-catenin. Nat. Immunol. 2009, 10:734-743.
24. Smith A., et al. M-CSF increases proliferation and phagocytosis while modulating receptor and transcription factor expression in adult human microglia. J. Neuroinflammation 2013, 10:85.
25. Melief J., et al. Phenotyping primary human microglia: tight regulation of LPS responsiveness. Glia 2012, 60:1506-1517.
26. Durafourt B.A., et al. Comparison of polarization properties of human adult microglia and blood-derived macrophages. Glia 2012, 60:717-727.
27. Lambert C., et al. Dendritic cell differentiation signals induce anti-inflammatory properties in human adult microglia. J. Immunol. 2008, 181:8288-8297.
28. Ponomarev E.D., et al. Development of a culture system that supports adult microglial cell proliferation and maintenance in the resting state. J. Immunol. Methods 2005, 300:32-46.
29. Re F., et al. Granulocyte-macrophage colony-stimulating factor induces an expression program in neonatal microglia that primes them for antigen presentation. J. Immunol. 2002, 169:2264-2273.
30. Esen N., Kielian T. Effects of low dose GM-CSF on microglial inflammatory profiles to diverse pathogen-associated molecular patterns (PAMPs). J. Neuroinflammation 2007, 4:10.
31. Marshall G.P., et al. Subventricular zone microglia possess a unique capacity for massive in vitro expansion. Glia 2008, 56:1799-1808.
32. Moussaud S., Draheim H.J. A new method to isolate microglia from adult mice and culture them for an extended period of time. J. Neurosci. Methods 2010, 187:243-253.
33. Klegeris A., et al. Modulation of human microglia and THP-1 cell toxicity by cytokines endogenous to the nervous system. Neurobiol. Aging 2005, 26:673-682.
34. De Groot C.J.A., et al. Isolation and characterization of adult microglial cells and oligodendrocytes derived from postmortem human brain tissue. Brain Res. 2000, 5:85-94.
35. Gibbons H.M., et al. Cellular composition of human glial cultures from adult biopsy brain tissue. J. Neurosci. Methods 2007, 166:89-98.
36. Lee S.C., et al. GM-CSF promotes proliferation of human fetal and adult microglia in primary cultures. Glia 1994, 12:309-318.
37. Serrano-Pozo A., et al. A phenotypic change but not proliferation underlies glial responses in Alzheimer disease. Am. J. Pathol. 2013, 182:2332-2344.
38. Kamphuis W., et al. Differential cell proliferation in the cortex of the appsweps1de9 alzheimer's disease mouse model. Glia 2012, 60:615-629.
39. Sapp E., et al. Early and progrssive accumulation of reactive microglia in the Huntington disease brain. J. Neuropathol. Exp. Neurol. 2001, 60:162-172.
40. Graeber M.B. Changing face of microglia. Science 2010, 330:783-788.
41. O'Keefe G.M., et al. Class II transactivator and class II MHC gene expression in microglia: modulation by the cytokines TGF-β, IL-4, IL-13 and IL-10. Eur. J. Immunol. 1999, 29:1275-1285.
42. Piskurich J., et al. Two distinct gamma interferon-inducible promoters of the major histocompatibility complex class II transactivator gene are differentially regulated by STAT1, interferon regulatory factor 1, and transforming growth factor beta. Mol. Cell. Biol. 1999, 19:431-440.
43. Pazmany T., Tomasi T.B. The major histocompatibility complex class II transactivator is differentially regulated by interferon-y and transforming growth factor-b in microglial cells. J. Neuroimmunol. 2006, 172:18-26.
44. Jones L.L., et al. Transforming growth factor beta's 1, 2 and 3 inhibit proliferation of ramified microglia on an astrocyte monolayer. Brain Res. 1998, 795:301-306.
45. Suzumura A., et al. Transforming growth factor-beta suppresses activation and proliferation of microglia in vitro. J. Immunol. 1993, 151:2150-2158.
46. Hashioka S., et al. Differential expression of interferon-y receptor on human glial cells in vivo and in vitro. J. Neuroimmunol. 2010, 225:91-99.
47. Parajuli B., et al. GM-CSF increases LPS-induced production of proinflammatory mediators via upregulation of TLR4 and CD14 in murine microglia. J. Neuroinflammation 2012, 9:268.
48. Carpentier P.A., et al. Glial toll-like receptor signaling in central nervous system infection and autoimmunity. Brain Behav. Immun. 2008, 22:140-147.
49. Jack C.S., et al. TLR signaling tailors innate immune responses in human microglia and astrocytes. J. Immunol. 2005, 175:4320-4330.
50. Casula M., et al. Toll-like receptor signaling in amyotrophic lateral sclerosis spinal cord tissue. Neuroscience 2011, 179:233-243.
51. Schmidt M., et al. Crucial role for human Toll-like receptor 4 in the development of contact allergy to nickel. Nat. Immunol. 2010, 11:814-819.
52. Cao H., et al. SIGLEC16 encodes a DAP12-associated receptor expressed in macrophages that evolved from its inhibitory counterpart SIGLEC11 and has functional and non-functional alleles in humans. Eur. J. Immunol. 2008, 38:2303-2315.
53. Angata T. Molecular diversity and evolution of the Siglec family of cell-surface lectins. Mol. Divers. 2006, 10:555-566.
54. Angata T., et al. Large-scale sequencing of the CD33-related Siglec gene cluster in five mammalian species reveals rapid evolution by multiple mechanisms. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:13251-13256.
55. Varki A. Multiple changes in sialic acid biology during human evolution. Glycoconj. J. 2009, 26:231-245.
56. Wang Y., Neumann H. Alleviation of neurotoxicity by microglial human Siglec-11. J. Neurosci. 2010, 30:3482-3488.
57. Cao H., et al. Comparative genomics indicates the mammalian CD33rSiglec locus evolved by an ancient large-scale inverse duplication and suggests all Siglecs share a common ancestral region. Immunogenetics 2009, 61:401-417.
58. Crocker P.R., et al. Siglecs and their roles in the immune system. Nat. Rev. Immunol. 2007, 7:255-266.
59. Varki A. Uniquely human evolution of sialic acid genetics and biology. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:8939-8946.
60. Hayakawa T., et al. A human-specific gene in microglia. Science 2005, 309:1693.
61. Bertram L., et al. Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. Am. J. Hum. Genet. 2008, 83:623-632.
62. Griciuc A., et al. Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 2013, 78:631-643.
63. Bradshaw E.M., et al. CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology. Nat. Neurosci. 2013, 16:848-850.
64. Brinkman-Van der Linden E.C.M., et al. CD33/Siglec-3 binding specificity, expression pattern, and consequences of gene deletion in mice. Mol. Cell. Biol. 2003, 23:4199-4206.
65. Lajaunias F., et al. Constitutive repressor activity of CD33 on human monocytes requires sialic acid recognition and phosphoinositide 3-kinase-mediated intracellular signaling. Eur. J. Immunol. 2005, 35:243-251.
66. Buchlis G., et al. Enhanced T cell function in a mouse model of human glycosylation. J. Immunol. 2013, 191:228-237.
67. Chou H-H., et al. Inactivation of CMP-N-acetylneuraminic acid hydroxylase occurred prior to brain expansion during human evolution. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:11736-11741.
68. Landry R.P., et al. Propentofylline, a CNS glial modulator does not decrease pain in post-herpetic neuralgia patients: in vitro evidence for differential responses in human and rodent microglia and macrophages. Exp. Neurol. 2012, 234:340-350.
69. Janabi N. Selective inhibition of cyclooxygenase-2 expression by 15-deoxy-δ12,1412,14-prostaglandin J2 in activated human astrocytes, but not in human brain macrophages. J. Immunol. 2002, 168:4747-4755.
70. Ding M., et al. Inducible nitric-oxide synthase and nitric oxide production in human fetal astrocytes and microglia: a kinetic analysis. J. Biol. Chem. 1997, 272:11327-11335.
71. Colasanti M., et al. Human ramified microglial cells produce nitric oxide upon Escherichia coli lipopolysaccharide and tumor necrosis factor α stimulation. Neurosci. Lett. 1995, 200:144-146.
72. Decendit A., et al. Malvidin-3-O-β glucoside, major grape anthocyanin, inhibits human macrophage-derived inflammatory mediators and decreases clinical scores in arthritic rats. Biochem. Pharmacol. 2013, 86:1461-1467.
73. Denis M. Human monocytes/macrophages: NO or no NO?. J. Leukoc. Biol. 1994, 55:682-684.
74. Liu J., et al. Expression of type II nitric oxide synthase in primary human astrocytes and microglia: role of IL-1beta and IL-1 receptor antagonist. J. Immunol. 1996, 157:3569-3576.
75. Lee S.C., et al. Induction of nitric oxide synthase activity in human astrocytes by interleukin-1β and interferon-γ. J. Neuroimmunol. 1993, 46:19-24.
76. Samy A., Igwe O. Regulation of IL-1β-induced cyclooxygenase-2 expression by interactions of Aβ peptide, apolipoprotein E and nitric oxide in human neuroglioma. J. Mol. Neurosci. 2012, 47:533-545.
77. Zhao M-L., et al. Inducible nitric oxide synthase expression is selectively induced in astrocytes isolated from adult human brain. Brain Res. 1998, 813:402-405.
78. Jung J-Y., et al. The intracellular environment of human macrophages that produce nitric oxide promotes growth of mycobacteria. Infect. Immun. 2013, 81:3198-3209.
79. Colton C.A., et al. APOE genotype-specific differences in human and mouse macrophage nitric oxide production. J. Neuroimmunol. 2004, 147:62-67.
80. Figuera-Losada M., et al. Inhibition of microglia activation as a phenotypic assay in early drug discovery. J. Biomol. Screen. 2014, 19:17-31.
81. Shi T-X., et al. Inhibitory constituents from the aerial parts of Polygala tenuifolia on LPS-induced NO production in BV2 microglia cells. Bioorg. Med. Chem. Lett. 2013, 23:5904-5908.
82. Smith A.M., et al. Valproic acid enhances microglial phagocytosis of amyloid-b1-42. Neuroscience 2010, 169:505-515.
83. Dragunow M., et al. Valproic acid induces caspase 3-mediated apoptosis in microglial cells. Neuroscience 2006, 140:1149-1156.
84. Chen P., et al. Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity. Neuroscience 2007, 149:203-212.
85. Shein N.a.A., et al. Histone deacetylase inhibitor ITF2357 is neuroprotective, improves functional recovery, and induces glial apoptosis following experimental traumatic brain injury. FASEB J. 2009, 23:4266-4275.
86. Gibbons H.M., et al. Valproic acid induces microglial dysfunction, not apoptosis, in human glial cultures. Neurobiol. Dis. 2011, 41:96-103.
87. Schughart K., et al. Controlling complexity: the clinical relevance of mouse complex genetics. Eur. J. Hum. Genet. 2013, 21:1191-1196.
88. Sabroe I., et al. Identifying and hurdling obstacles to translational research. Nat. Rev. Immunol. 2007, 7:77-82.
89. Smith A., et al. Isolation and culture of adult human microglia within mixed glial cultures for functional experimentation and high-content analysis. Microglia 2013, 41-51. Humana Press. B. Joseph, J.L. Venero (Eds.).
90. Lambert C., et al. Distinct migratory and cytokine responses of human microglia and macrophages to ATP. Brain Behav. Immun. 2010, 24:1241-1248.
91. Perry V.H. Contribution of systemic inflammation to chronic neurodegeneration. Acta Neuropathol. 2010, 120:277-286.
92. Ramsey J., et al. Identification of an age-dependent biomarker signature in children and adolescents with autism spectrum disorders. Mol. Autism 2013, 4:27.
93. Phadwal K., et al. A novel method for autophagy detection in primary cells: impaired levels of macroautophagy in immunosenescent T cells. Autophagy 2012, 8:677-689.
94. Schwarz, E. et al. Identification of subgroups of schizophrenia patients with changes in either immune or growth factor and hormonal pathways. Schizophr. Bull. (in press).
95. García-Berrocoso T., et al. From brain to blood: new biomarkers for ischemic stroke prognosis. J. Proteomics 2013, 94:138-148.
96. Henriksen K., et al. The future of blood-based biomarkers for Alzheimer's disease. Alzheimers Dement. 2013, 10.1016/j.jalz.2013.01.013.
97. Sena E.S., et al. Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. PLoS Biol. 2010, 8:e1000344. 10.1371/journal.pbio.1000344.
98. Hartung T., Zurlo J. Alternative approaches for medical countermeasures to biological and chemical terrorism and warfare. ALTEX 2012, 29:251-260.
99. Dragunow M. High-content analysis in neuroscience. Nat. Rev. Neurosci. 2008, 9:779-788.
100. Jowers C.T., et al. The cell injury device: a high-throughput platform for traumatic brain injury research. J. Neurosci. Methods 2013, 218:1-8.
101. Politis M., et al. Imaging of microglia in patients with neurodegenerative disorders. Front. Pharmacol. 2012, 3. 10.3389/fphar.2012.00096.
102. Kaye J., Finkbeiner S. Modeling Huntington's disease with induced pluripotent stem cells. Mol. Cell. Neurosci. 2013, 56:50-64.
103. An M.C., et al. Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells. Cell Stem Cell 2012, 11:253-263.
104. Hartfield E.M., et al. Cellular reprogramming: a new approach to modelling Parkinson's disease. Biochem. Soc. Trans. 2012, 40:1152-1157.
105. Tran N.N., et al. Modeling schizophrenia using induced pluripotent stem cell-derived and fibroblast-induced neurons. Schizophr. Bull. 2013, 39:4-10.
106. Brennand K.J., et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature 2011, 473:221-225.
107. Juopperi T., et al. Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington's disease patient cells. Mol. Brain 2012, 5:17.
108. Napoli I., et al. Microglial precursors derived from mouse embryonic stem cells. Glia 2009, 57:1660-1671.
109. Almeida S., et al. Induced pluripotent stem cell models of progranulin-deficient frontotemporal dementia uncover specific reversible neuronal defects. Cell Rep. 2012, 2:789-798.
110. Czepiel M., et al. Differentiation of induced pluripotent stem cells into functional oligodendrocytes. Glia 2011, 59:882-892.
111. Wang S., et al. Human iPSC-derived oligodendrocyte progenitor cells can myelinate and rescue a mouse model of congenital hypomyelination. Cell Stem Cell 2013, 12:252-264.
112. Pouya A., et al. Human induced pluripotent stem cells differentiation into oligodendrocyte progenitors and transplantation in a rat model of optic chiasm demyelination. PLoS ONE 2011, 6:e27925. 10.1371/journal.pone.0027925.
113. Lancaster M.A., et al. Cerebral organoids model human brain development and microcephaly. Nature 2013, 501:373-379.
114. Verwer R.W.H., et al. Cells in human postmortem brain tissue slices remain alive for several weeks in culture. FASEB J. 2002, 16:54-60.
115. Chaichana K.L., et al. Preservation of glial cytoarchitecture from ex vivo human tumor and non-tumor cerebral cortical explants: a human model to study neurological diseases. J. Neurosci. Methods 2007, 164:261-270.
116. Wu L., et al. Neural stem cells improve neuronal survival in cultured postmortem brain tissue from aged and Alzheimer patients. J. Cell. Mol. Med. 2008, 12:1611-1621.
117. Merz F., et al. Organotypic slice cultures of human glioblastoma reveal different susceptibilities to treatments. Neuro Oncol. 2013, 15:670-681.
118. Sebollela A., et al. Amyloid-β oligomers induce differential gene expression in adult human brain slices. J. Biol. Chem. 2012, 287:7436-7445.
119. Haycock J. 3D cell culture: a review of current approaches and techniques. 3D Cell Culture 2011, 1-15. Humana Press. J.W. Haycock (Ed.).
120. Zervantonakis I., et al. Microfluidic devices for studying heterotypic cell-cell interactions and tissue specimen cultures under controlled microenvironments. Biomicrofluidics 2011, 5:13406.
121. Huh D., et al. Acoustically detectable cellular-level lung injury induced by fluid mechanical stresses in microfluidic airway systems. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:18886-18891.
122. Huh D., et al. Reconstituting organ-level lung functions on a chip. Science 2010, 328:1662-1668.
123. Esch M.B., et al. The role of body-on-a-chip devices in drug and toxicity studies. Annu. Rev. Biomed. Eng. 2011, 13:55-72.
124. Park J., et al. Microfluidic compartmentalized co-culture platform for CNS axon myelination research. Biomed. Microdevices 2009, 11:1145-1153.
125. Park J.W., et al. Microfluidic culture platform for neuroscience research. Nat. Protoc. 2006, 1:2128-2136.
126. Berdichevsky Y., et al. Microfluidics and multielectrode array-compatible organotypic slice culture method. J. Neurosci. Methods 2009, 178:59-64.
127. Berdichevsky Y., et al. Building and manipulating neural pathways with microfluidics. Lab Chip 2010, 10:999-1004.
128. Griep L.M., et al. BBB ON CHIP: microfluidic platform to mechanically and biochemically modulate blood-brain barrier function. Biomed. Microdevices 2013, 15:145-150.
129. Hartung T. Toxicology for the twenty-first century. Nature 2009, 460:208-212.
130. Shintu L., et al. Metabolomics-on-a-chip and predictive systems toxicology in microfluidic bioartificial organs. Anal. Chem. 2012, 84:1840-1848.
131. Huh D., et al. From 3D cell culture to organs-on-chips. Trends Cell Biol. 2011, 21:745-754.
132. Olah M., et al. An optimized protocol for the acute isolation of human microglia from autopsy brain samples. Glia 2012, 60:96-111.
133. Durafourt B., et al. Isolating, culturing, and polarizing primary human adult and fetal microglia. Microglia 2013, 199-211. Humana Press. B. Joseph, J.L. Venero (Eds.).
134. Fricker M., et al. Primary phagocytosis of viable neurons by microglia activated with LPS or Abeta is dependent on calreticulin/LRP phagocytic signalling. J. Neuroinflammation 2012, 9:196.
135. Satoh J-i., et al. Immunohistochemical characterization of microglia in Nasu-Hakola disease brains. Neuropathology 2011, 31:363-375.
136. Sessa G., et al. Distribution and signaling of TREM2/DAP12, the receptor system mutated in human polycystic lipomembraneous osteodysplasia with sclerosing leukoencephalopathy dementia. Eur. J. Neurosci. 2004, 20:2617-2628.
137. Kiialainen A., et al. Dap12 and Trem2, molecules involved in innate immunity and neurodegeneration, are co-expressed in the CNS. Neurobiol. Dis. 2005, 18:314-322.
138. Lee S.C., et al. Macrophage colony-stimulating factor in human fetal astrocytes and microglia. Differential regulation by cytokines and lipopolysaccharide, and modulation of class II MHC on microglia. J. Immunol. 1993, 150:594-604.
139. Akiyama H., et al. Expression of the receptor for macrophage colony stimulating factor by brain microglia and its upregulation in brains of patients with Alzheimer's disease and amyotrophic lateral sclerosis. Brain Res. 1994, 639:171-174.
140. Raivich G., et al. Regulation of MSCF receptors on microglia in the normal and injured mouse central nervous system: a quantitative immunofluorescence study using confocal laser microscopy. J. Comp. Neurol. 1998, 395:342-358.
141. Meda L., et al. Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature 1995, 374:647-650.
142. Tsuda M., et al. IFN-γ receptor signaling mediates spinal microglia activation driving neuropathic pain. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:8032-8037.
143. Wei Y-P., et al. Expression of IFN-gamma in cerebrovascular endothelial cells from aged mice. J. Interferon Cytokine Res. 2000, 20:403-409.
144. Tchilian E., et al. Molecular cloning of two isoforms of the murine homolog of the myeloid CD33 antigen. Blood 1994, 83:3188-3198.
145. Sweitzer S., Leo J. Propentofylline: glial modulation, neuroprotection, and alleviation of chronic pain. Methylxanthines 2011, 235-250. Springer, Berlin Heidelberg. B. Fredholm (Ed.).
146. Sweitzer S.M., et al. Propentofylline attenuates vincristine-induced peripheral neuropathy in the rat. Neurosci. Lett. 2006, 400:258-261.
147. Tawfik V.L., et al. Reprint of "Efficacy of propentofylline, a glial modulating agent, on existing mechanical allodynia following peripheral nerve injury" [Brain Behav. Immun. 21 (2007) 238-246]. Brain Behav. Immun. 2007, 21:677-685.
148. Streit W.J., Xue Q.S. The brain's aging immune system. Aging Dis. 2010, 1:254-261.
149. Sugaya K., et al. Topographic associations between DNA fragmentation and Alzheimer's disease neuropathology in the hippocampus. Neurochem. Int. 1997, 31:275-281.
150. Lassmann H., et al. Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ. Acta Neuropathol. 1995, 89:35-41.
151. Yang F., et al. Antibody to caspase-cleaved actin detects apoptosis in differentiated neuroblastoma and plaque-associated neurons and microglia in Alzheimer's disease. Am. J. Physiol. 1998, 152:379-389.
152. Shultz L.D., et al. Humanized mice in translational biomedical research. Nat. Rev. Immunol. 2007, 7:118-130.
153. Bruce-Keller A.J., et al. Cognitive impairment in humanized APP x PS1 mice is linked to Aβ1-42 and NOX activation. Neurobiol. Dis. 2011, 44:317-326.
154. Li M., et al. Development of a humanized C1q A chain knock-in mouse: assessment of antibody independent ß-amyloid induced complement activation. Mol. Immunol. 2008, 45:3244-3252.
155. Illes Z., et al. Copolymer effects on microglia and T cells in the central nervous system of humanized mice. Eur. J. Immunol. 2005, 35:3683-3693.
156. Lee M., et al. Neurotoxins released from interferon-gamma-stimulated human astrocytes. Neuroscience 2013, 229:164-175.
157. Hashioka S., et al. Inhibition of human astrocyte and microglia neurotoxicity by calcium channel blockers. Neuropharmacology 2012, 63:685-691.
158. Hashioka S., et al. Proton pump inhibitors exert anti-inflammatory effects and decrease human microglial and monocytic THP-1 cell neurotoxicity. Exp. Neurol. 2009, 217:177-183.
159. Klegeris A., et al. Prolyl endopeptidase is revealed following SILAC analysis to be a novel mediator of human microglial and THP-1 cell neurotoxicity. Glia 2008, 56:675-685.
160. Streit W., et al. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease. Acta Neuropathologica 2009, 118:475-485.
161. Smith A., et al. Adult human glia, pericytes and meningeal fibroblasts respond similarly to IFNg but not to TGFβ1 or M-CSF. PLoS One 2013, (in press).